Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 3/2000

01-03-2000 | Adis Drug Evaluation

Docetaxel

An Update of its Use in Advanced Breast Cancer

Authors: David P. Figgitt, Lynda R. Wiseman

Published in: Drugs | Issue 3/2000

Login to get access

Summary

Abstract

Docetaxel, a semisynthetic member of the taxoid class of antineoplastic agents, is effective in the treatment of patients with advanced (locally advanced or metastatic) breast cancer. Reported objective response rates for docetaxel 100 mg/m2 ranged from 54 to 69% and 53 to 82% as first-line monotherapy or combination therapy, respectively. Objective response rates of 23 to 65% and 30 to 81% have been reported for docetaxel as second-line monotherapy or combination therapy, respectively. In Japanese studies, second-line docetaxel 60 mg/m2 produced objective response rates of 42 to 55%.
At the recommended dose of 100 mg/m2 given as a 1-hour intravenous (IV) infusion every 3 weeks, docetaxel had significantly greater efficacy than doxorubicin, mitomycin plus vinblastine and methotrexate plus fluorouracil, and similar efficacy to fluorouracil plus vinorelbine in pretreated patients with advanced breast cancer.
In chemotherapy-naive patients, first-line combined therapy with docetaxel and doxorubicin had significantly greater efficacy than doxorubicin plus cyclophosphamide. Promising results have been achieved in phase I/II trials of a weekly regimen of docetaxel (generally 30 to 45 mg/m2). Preliminary data indicate a potential role for docetaxel in the neoadjuvant therapy of early breast cancer.
The major dose-limiting adverse event associated with docetaxel is neutropenia. Although other adverse events are common, the tolerability profile of docetaxel is generally acceptable in the majority of patients, particularly in comparison with other antineoplastic regimens.
Conclusions: Although no single standard regimen has been identified as optimal for the treatment of advanced breast cancer, phase III trials have shown that docetaxel has improved efficacy over doxorubicin alone (considered one of the current gold standards), methotrexate/fluorouracil and mitomycin/vinblastine in second-line therapy. In combination with doxorubicin, docetaxel has demonstrated better efficacy than doxorubicin/cyclophosphamide in first-line therapy. These results provide a basis for therapy choice in advanced breast cancer. Clinical trials comparing docetaxel monotherapy versus paclitaxel monotherapy and versus docetaxel combination therapy are warranted. The role of docetaxel in the adjuvant and neoadjuvant treatment of early breast cancer is being evaluated.

Overview of Pharmacodynamic Properties

Docetaxel, a member of the taxoid class of antineoplastic agents, is derived from a precursor obtained from the European yew. The principal mechanism by which docetaxel is thought to exert its cytotoxic activity is through enhancement and stabilisation of microtubule assembly, while simultaneously preventing microtubule depolymerisation. In turn, this prevents normal cell division. Docetaxel has also been shown to induce cell death by apoptosis and cell lysis, to phosphorylate the apoptosis-blocking oncoprotein bcl-2 and to have antiangiogenic properties.
In vitro, docetaxel has often shown greater cytotoxic activity than that of paclitaxel against a range of human tumour cells, including breast cancer cells. Docetaxel has synergistic in vitro cytotoxicity when combined with several other agents, including topotecan, tamoxifen, fulvestrant, edatrexate and trastuzumab. Combined with irinotecan, docetaxel has antitumour activity in human breast tumour-bearing animals; against human tumour xenografts in mice, docetaxel enhances the activity of capecitabine. Docetaxel has also demonstrated in vivo antitumour activity alone and synergistic in vivo activity in combination with fluorouracil, cyclophosphamide, etoposide, methotrexate or vinorelbine. The radiopotentiating activity of docetaxel has been shown in animal models.
A number of mechanisms of cellular resistance to docetaxel have been identified: alterations in the tubulin subunits, increased expression of the multidrug resistance protein (mdr-1) gene-encoded membrane glycoprotein p170mdr−1, expression of the membrane phosphoglycoprotein MRP, and expression of the transmembrane glycoprotein p185c-erbB2. There is some evidence that resistance to doxorubicin or paclitaxel may not result in complete cross-resistance to docetaxel.

Overview of Pharmacokinetic Properties

At the recommended docetaxel dose of 100 mg/m2 administered as a 1-hour infusion, the pharmacokinetic profile of docetaxel is best described as a 3-compartment model. In contrast with paclitaxel, the disposition of docetaxel is linear. Approximately 93 to 94% of docetaxel is protein bound at clinically relevant concentrations. High interindividual variability of plasma binding most likely results from variable ga1-acid glycoprotein (AAG) concentrations.
Population pharmacokinetic studies indicate that docetaxel clearance is a strong predictor of grade 4 neutropenia and febrile neutropenia, whereas cumulative dose best predicts fluid retention. Clearance appears to be reduced in patients with elevated liver enzymes.
Docetaxel is primarily metabolised by cytochrome P450 enzymes to yield 4 inactive metabolites. The predominant route of docetaxel elimination is faecal excretion via the biliary tract, with approximately 4% of a dose eliminated unchanged in the urine. There appears to be no cross-race difference in docetaxel elimination between Western and Japanese patients.
In phase I clinical trials, the pharmacokinetic profile of docetaxel was not significantly altered by coadministration with fluorouracil, vinorelbine, ifosfamide, epirubicin or methotrexate. Docetaxel did not significantly affect the pharmacokinetics of doxorubicin. When docetaxel was administered before cisplatin as part of sequential therapy, cisplatin white blood cell DNA-adduct levels were significantly lower than when docetaxel was administered after cisplatin. Oral dexamethasone premedication 8mg twice daily for 5 days did not affect the pharmacokinetics of docetaxel.

Clinical Efficacy

Dose-finding studies established the optimal dose and schedule of docetaxel as 60 to 100 mg/m2 given as a 1-hour intravenous (IV) infusion every 3 weeks. In Japanese studies, the optimal docetaxel dose was established as 60 mg/m2 by 1-hour IV infusion every 3 weeks.
Monotherapy: Objective response rates obtained with docetaxel as second-line monotherapy in phase I/II trials have ranged from 23 to 65%. A large multicentre UK study of docetaxel in 331 pretreated patients with locally advanced or metastatic breast cancer yielded an objective response rate of 46% and a median survival of 194 days. In Japanese studies, docetaxel 60 mg/m2 produced objective response rates of 42 to 55% in 186 patients.
Docetaxel as second-line monotherapy demonstrated significantly better clinical efficacy (in terms of response rate and, in some studies, time to disease progression and overall survival) than doxorubicin, mitomycin/vinblastine or methotrexate/fluorouracil. However, its efficacy appeared similar to that of fluorouracil/vinorelbine in a preliminary report.
Although limited, data from trials evaluating weekly docetaxel administration indicate that response rates of about 55% can be achieved in previously treated patients with advanced breast cancer.
Objective response rates to docetaxel monotherapy in chemotherapy-naive patients have ranged between 54 and 69% in phase II trials. A large multicentre study (n = 288) reported objective responses in 59% of patients with a median duration of 9.2 months and a median time to disease progression of 7 months. Docetaxel as first-line monotherapy has not been adequately investigated compared with other antineoplastic agents.
Combination therapy: As second-line therapy, objective response rates ranged from 30 to 81% in trials that evaluated docetaxel in combination with fluorouracil, vinorelbine, epirubicin, doxorubicin, cisplatin, gemcitabine or mitoxantrone.
As first-line therapy, the combination of docetaxel and doxorubicin has been the most widely evaluated. Objective response rates for docetaxel/doxorubicin ranged from 55 to 78%, similar to those achieved for docetaxel in combination with other antineoplastic agents (range: 53 to 82%), including cisplatin, cyclophosphamide, epirubicin, mitoxantrone and vinorelbine.
Docetaxel 75 mg/m2 plus doxorubicin 50 mg/m2 produced a significantly greater objective response rate than doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 (60 vs 47%, respectively; p = 0.008) in a phase III comparative trial in 429 anthracycline-naive patients. Response rates were also higher in subgroups of patients with unfavourable prognostic factors treated with combined docetaxel/doxorubicin than in those treated with doxorubicin/cyclophosphamide.
Limited data indicate that docetaxel, particularly in combination with doxorubicin, has efficacy in the neoadjuvant treatment of early breast cancer. Large ongoing trials should clarify the role of docetaxel in the adjuvant/neoadjuvant setting.
Sequential therapy: Docetaxel administered sequentially with doxorubicin plus cyclophosphamide produced a response rate of 71%, with a median duration of 53 weeks, median time to disease progression of 46 weeks and a median overall survival duration of 25 months. Alternate administration of docetaxel with fluorouracil/epirubicin/cyclophosphamide gave objective response rates of 64 to 68% depending on the order of administration.

Overview of Pharmacoeconomic Considerations

Cost-utility analyses, compiled in the absence of direct comparative clinical data, suggest that docetaxel offers utility gains versus paclitaxel in the treatment of metastatic breast cancer. The incremental cost for these gains is within the accepted range for healthcare interventions.

Tolerability

The most common adverse events (all grades) associated with docetaxel in phase II trials were neutropenia (91.5%), alopecia (83.4%), asthenia (68.2%), dermatological effects (64.3%), neurosensory effects (47.9%), fluid retention (46.7%), nausea (44.5%), diarrhoea (43.3%), mucositis/stomatitis (42.7%), fever (35.8%) and hypersensitivity reactions (31.3%). Neutropenia is the primary dose-limiting adverse event associated with docetaxel, occurring within 5 to 12 days of docetaxel administration and lasting for a mean duration of 7 to 8 days. Docetaxel 30 to 45 mg/m2 given as a weekly infusion appears to be associated with a lower incidence of haematological adverse events than the standard 3-weekly regimen.
Grade 4 neutropenia occurred with similar frequency in docetaxel or doxorubicin-treated patients in a comparative study, although the incidence of febrile neutropenia and severe infections was statistically higher in doxorubicin-treated patients. Docetaxel was also associated with a lower incidence of toxic deaths, anaemia, need for red blood cell transfusion and thrombocytopenia than doxorubicin. Quality-of-life evolution was relatively stable and not statistically significantly different between docetaxel- and doxorubicin-treated patients.
Overall, docetaxel tolerability compared favourably with combinations of mitomycin/vinblastine, methotrexate/fluorouracil and appeared better than fluorouracil/vinorelbine as second-line therapy in patients with advanced breast cancer. However, docetaxel was generally associated with a higher incidence of haematological adverse events than each of these drug combinations.
Docetaxel is commonly associated with neurological toxicity and, in phase III studies, this adverse event and fluid retention occurred more frequently in docetaxel-treated patients than in all other comparator treatment groups. Fluid retention, associated with the cumulative docetaxel dose, is possibly related to docetaxel-induced capillary permeability and insufficient lymphatic drainage.
Corticosteroid premedication delays the onset and reduces the incidence and severity of fluid retention and reduces the severity of hypersensitivity reactions; however, it has no effect on the incidence or severity of neurological events. Cardiac toxicity is not commonly associated with docetaxel, and the incidence of doxorubicin-induced cardiomyopathy does not appear to be influenced by docetaxel.

Dosage and Administration

The recommended starting dose and schedule of docetaxel for patients with advanced breast cancer is 60 to 100 mg/m2 in the US and 100 mg/m2 in Europe, administered as a 1-hour IV infusion every 3 weeks. Docetaxel 60 mg/m2 every 3 weeks is the recommended dose in Japan. The dose of docetaxel should be decreased or discontinued in patients experiencing febrile neutropenia, myelosuppression, severe or cumulative cutaneous reactions, severe peripheral neuropathy, or elevated liver function. All patients should receive oral corticosteroid premedication for 3 days to reduce the incidence and severity of fluid retention and the severity of hypersensitivity reactions.
Literature
1.
2.
3.
Docetaxel launched and OCs nearer approval in Japan. Inpharma 1997 Jul 5; 1094: 21
4.
5.
Perez EA. Current management of metastatic breast cancer. Semin Oncol 1999; 26 Suppl. 12: 1–10PubMed
6.
Fornier M, Munster P, Seidman AD. Update on the management of advanced breast cancer. Oncology 1999; 13: 647–58PubMed
7.
Aapro MS. Combining new agents with anthracyclines in metastatic breast cancer: an overview of recent findings. Semin Oncol 1999 Feb; 26 Suppl. 3: 17–21PubMed
8.
Eisenhauer EA, Vermorken JB. The taxoids: comparative clinical pharmacology and therapeutic potential. Drugs 1998 Jan; 55: 5–30PubMedCrossRef
9.
Docetaxel (Taxotere): a new option for the treatment of homone-refractory prostate cancer. Proceedings of a symposium [Guest editor: Vogelzang,N]. Semin Oncol 1999; 26 (5) Suppl. 17: 1–68
10.
Fulton B, Spencer CM. Docetaxel: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer. Drugs 1996 Jun; 51: 1075–92PubMedCrossRef
11.
Wiseman LR, Spencer CM. Paclitaxel: an update of its use in the treatment of metastatic breastcancer and ovarian and other gynaecological cancer. Drugs Aging 1998 Apr; 12: 305–34PubMedCrossRef
12.
Hortobagyi GN. Recent progress in the clinical development of docetaxel (Taxotere). Semin Oncol 1999; 26 Suppl. 9: 32–6PubMed
13.
Mason K, Kishi K, Hunter N, et al. In vivo chemoradiotherapy with docetaxel and fractionated radiation [abstract no. 1705]. Proc Am Soc Clin Oncol 1999; 18: 442
14.
Milas L, Milas MM, Mason KA. Combination of taxanes with radiation: preclinical studies. Semin Radiat Oncol 1999; 9(2) Suppl. 1: 12–26PubMed
15.
Banerjee S, Brown DL, Fallis AG, et al. Effects of taxotere on two human cancer cell lines [abstract no. 1541]. 88th Annu Meet Am Assoc Cancer Res 1997 Apr 12: 229
16.
Schimming R, Mason KA, Hunter N, et al. Lack of correlation between mitotic arrest or apoptosis and antitumor effect of docetaxel. Cancer Chemother Pharmacol 1999 Feb; 43: 165–72PubMedCrossRef
17.
Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res 1997; 57: 229–33PubMed
18.
Berchem GJ, Bosseler M, Mine N, et al. Nanomolar range docetaxel treatment sensitizes MCF-7 cells to chemotherapy induced apoptosis, induces G2M arrest and phosphorylates bcl-2. Anticancer Res 1999 Jan–Feb; 19: 535–40PubMed
19.
Kraus LA, Schmid SM, Coffield RT, et al. The mechanism of action of docetaxel and paclitaxel in xenograft models is not limited to Bcl-2 phosphorylation [abstract no. 3809]. Proceedings of the American Association Cancer Research 1999; 40: 578
20.
Barendsz-Janson AF, Toebes EAH, Hillen HFP, et al. Anti-angiogenic effect of tumor-drugs [abstract no. 298]. Ann Oncol 1998; 9 Suppl. 2: 78
21.
Plasencia C, Taron M, Abad A, et al. Cytotoxic effects of topotecan combined with various active G2/M phase anticancer drugs in panel of human tumor derived cell lines [abstract no. 647]. Ann Oncol 1998; 9 Suppl. 4: 135
22.
Ferlini C, Scambia G, Distefano M, et al. Synergistic antiproliferative activity of tamoxifen and docetaxel on three oestrogen receptor-negative cancer cell lines is mediated by the induction of apoptosis. Br J Cancer 1997; 75(6): 884–91PubMedCrossRef
23.
Chou TC, Otter GM, Sirotnak FM. Schedule-dependent synergism of taxol or taxotere with edatrexate against human breast cancer cells in vitro. Cancer Chemother Pharmacol 1996; 37: 222–8PubMedCrossRef
24.
Hübner B, Eckert K, Maurer HR. Synergistic and antagonistic interactions between docetaxel and interferon-β on growth of human breast cancer cells in vitro. Int J Oncol 1996 Oct; 9: 625–8PubMed
25.
Hahm HA, Casero RA, Woster PM, et al. Combination therapy with polyamine analogs and chemotherapeutic agents in breast cancer cell lines, in vitro [abstract no. 3902]. Proceedings of the American Association Cancer Research 1999; 40: 592
26.
Konecny K, Pegram MD,Beryt M, et al. Therapeutic advantage of chemotherapy drugs in combination with Herceptin against human breast cancer cells with HER-2/neu overexpression [abstract no. 467]. Breast Cancer Res Treat 1999; 57(1): 114
27.
Zeng S, Fu T, Johnson KR, et al. In vitro evaluation of sequential-dependent combination of docetaxel and doxorubicin in human breast cancer cells [abstract no. 3884]. Proceedings of the American Association Cancer Research 1999 March; 40: 589
28.
Dykes DJ, Bissery MC, Harrison J SD, et al. Response of human tumor xenografts in athymic nude mice to docetaxel (RP 56976, Taxotere). Invest New Drugs 1995; 13: 1–11PubMedCrossRef
29.
Bissery MC, Couteau C, Oulid-Aïssa D. Docetaxel in combination with irinotecan: prediction of clinical maximum tolerated dose [abstract]. 33rd Proc Am Soc Clin Oncol 1997 May 17; 16: 221
30.
Sawada N, Ishikawa T, Fukase Y, et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/Taxotere in human cancer xenografts. Clin Cancer Res 1998 Apr; 4: 1013–9PubMed
31.
Eckardt JR. Antitumor activity of docetaxel. Am J Health System Pharm 1997 Dec 15; 54 Suppl. 2: S2–6
32.
Mason KA, Hunter NR, Milas M, et al. Docetaxel enhances tumor radioresponse in vivo. Clin Cancer Res 1997 Dec; 3 (12 Pt 1): 2431–8PubMed
33.
Distelmans W, Storme G. The effect of pretreatment with docetaxel (taxotere; RP 56976) on irradiated subcutaneous MA 16/C murine tumors. J Exp Clin Cancer Res 1999; 18: 167–72PubMed
34.
Tampellini M, Filipski E, Liu XH, et al. Docetaxel chronopharmacology in mice. Cancer Res 1998 Sep 1; 58: 3896–904PubMed
35.
van Ark-Otte J, Samelis G, Rubio G, et al. Effects of tubulin-inhibiting agents in human lung and breast cancer cell lines with different multidrug resistance phenotypes. Oncol Rep 1998 Jan–Feb; 5: 249–55PubMed
36.
Vanhoefer U, Cao S, Harstrick A, et al. Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP). Ann Oncol 1997 Dec; 8: 1221–8PubMedCrossRef
37.
Yu D, Liu B, Jing T, et al. Overexpression of both p185c-erbB2 and p170mdr−1 renders breast cancer cells highly resistant to taxol. Oncogene 1998 Apr 23; 16: 2087–94PubMedCrossRef
38.
Riou J-F, Naudin A, Lavelle F. Effects of taxotere on murine and human tumor cell lines. Biochem Biophys Res Commun 1992 Aug 31; 187: 164–70PubMedCrossRef
39.
Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 1999 Feb; 36: 99–114PubMedCrossRef
40.
Bruno R, Sanderink GJ. Pharmacokinetics and metabolism of Taxotere™ (docetaxel). Cancer Surv 1993; 17: 305–13PubMed
41.
Aapro MS, Zulian G, Alberto P, et al. Phase I and pharmacokinetic study of RP 56976 in a new ethanol-free formulation of taxotere [abstract no. 208]. Ann Oncol 1992; 3 Suppl. 5: 53
42.
Burris H, Irvin R, Kuhn J, et al. Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion. J Clin Oncol 1993 May; 11: 950–8PubMed
43.
Extra J-M, Rousseau F, Bruno R, et al. Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res 1993 Mar 1; 53: 1037–42PubMed
44.
Kearns CM. Pharmacokinetics of the taxanes. Pharmacotherapy 1997 Part 2, Sep–Oct 5; 17: 105S–9SPubMed
45.
Bruno R, Riva A, Hille D, et al. Pharmacokinetic and pharmacodynamic properties of docetaxel: results of phase I and phase II trials. Am J Health System Pharm 1997 Dec 15; 2 Suppl. 2: S16–19
46.
McLeod HL, Kearns CM, Kuhn JG, et al. Evaluation of the linearity of docetaxel pharmacokinetics. Cancer Chemother Pharmacol 1998 Jul; 42: 155–9PubMedCrossRef
47.
Urien S, Barré J, Morin C, et al. Docetaxel serum protein binding with high affinity to alpha-1-acid glycoprotein. Invest New Drugs 1996; 14(2): 147–51PubMedCrossRef
48.
Veyrat-Follet C, Bruno R, Montay G, et al. Application of clinical trial simulation in exploring the safety profile of docetaxel (D) in cancer patients [abstract no. PIII-88]. Clin Pharmacol Ther 1999 Feb; 65: 198CrossRef
49.
Bruno R, Hille D, Riva A, et al. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1998 Jan; 16: 187–96PubMed
50.
Bruno R, Vivier N, Montay G, et al. The cycle-to-cycle variability of docetaxel pharmacokinetics (PK) assessed by population PK analysis [abstract no. 751]. Eur J Cancer 1999; 35 Suppl. 4: S194CrossRef
51.
Tanigawara Y, Sasaki Y, Otsu T, et al. Population pharmacokinetics of docetaxel in Japanese patients [abstract no. 1518]. Proc Am Soc Clin Oncol 1996 Mar; 15: 479
52.
Baker SD, Ravdin P, Aylesworth C, et al. A phase I and pharmacokinetic (PK) study of docetaxel in cancer patients with liver dysfunction due to malignancies [abstract no. 388]. Ann Oncol 1998; 9 Suppl. 2: 102
53.
de Valeriola D, Brassinne C, Kerger J, et al. Clinical and pharmacokinetic phase I study of docetaxel (TXT) combined to continuous infusion (CI) of 5-fluorouracil (FU) in advanced cancer patients [abstract no.774]. Proc Am Soc Clin Oncol 1997; 16: 221a
54.
Fumoleau P, Delecroix V, Perrocheau G, et al. Final results of a phase I dose finding and pharmacokinetic (PK.) study of docetaxel in combination with vinorelbine in metastatic breast cancer [abstract no. 606P]. Ann Oncol 1996; 7 Suppl. 5: 126
55.
Schrijvers D, Pronk L, Highley M, et al. Sequence-dependent pharmacokinetics (PK) of ifosfamide (I) combined with docetaxel (D) [abstract no. OP 176]. Eur J Cancer A 1998 May; 34 Suppl. 2: S39
56.
Esposito M, Venturini M, Vannozzi MO, et al. Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients. J Clin Oncol 1999; 17(4): 1132–40PubMed
57.
Cattel L, Airoldi M, Brusa P, et al. Pharmacokinetic (PK) interaction between epidoxorubicin (EPI) and docetaxel (TXT) in patients with metastatic breast cancer (MBC) [abstract no. 1318]. Eur J Cancer 1999; 35 Suppl. 4: S328CrossRef
58.
Tranchand B, Peguy M, Guillot A, et al. A pharmacokinetic study of methotrexate and docetaxel given in association during a phase I trial [abstract no. 362]. Ann Oncol 1998; 9 Suppl. 2:95
59.
Schüller J, Czejka M, Krexner E, et al. Pharmacokinetic (PK) interaction of the combination of doxorubicin (DOX) and Taxotere (TXT) [abstract no. 607O]. Ann Oncol 1998; 9 Suppl. 4: 126CrossRef
60.
D’Incalci M, Schüller J, Colombo T, et al. Taxoids in combination with anthracyclines and other agents: pharmacokinetic considerations. Semin Oncol 1998 Dec; 25 Suppl. 13: 16–20PubMed
61.
de Valeriola D, Awada A, Van Vreckem A, et al. Influence of amifostine (A) on the toxicity and pharmacokinetics (PK) of docetaxel (D) in breast cancer patients: an EORTIC-IDBBC study [abstract no. 76]. Eur J Cancer A 1998 Sep; 34 Suppl. 5: S19CrossRef
62.
Schüller J, Czejka M, Krexner E, et al. Amifostine (AM) differently influences pharmacokinetics (PK) of selected cystostatic agents (CY) [abstract no. 1109]. Eur J Cancer A 1997 Sep; 33 Suppl. 8: S245CrossRef
63.
Schellens JHM, Ma J, Bruno R, et al. Pharmacokinetics of cisplatin and Taxotere (docetaxel) and WBC DNA-adduct formation of cisplatin in the sequence Taxotere/cisplatin and cisplatin/Taxotere in a phase I/II study in solid tumor patients [abstract no. 323]. Proc Am Soc Clin Oncol 1994 Mar; 13: 132
64.
Bruno R, Vivier N, Houver C, et al. Lack of influence of dexamethasone premedication on docetaxel (Taxotere) pharmacokinetics [abstract no. 335]. Ann Oncol 1996; 7 Suppl. 1: 96
65.
Crown J. A review of the efficacy and safety of docetaxel as a monotherapy in metastatic breast cancer. Semin Oncol 1999 Feb; 26 Suppl. 3: 5–9PubMed
66.
Trudeau ME. Phase I–II studies of docetaxel as a single agent in the treatment of metastatic breast cancer. Semin Oncol 1999; 26 Suppl. 8: 21–6PubMed
67.
Palacio I, Fra J, Lacave AJ, et al. The ideal dose of taxotere (T) in patients with metastatic breast cancer (MBC) previously treated with antracyclines (A): a dose finding study of the GON (“Grupo Oncologico del Norte”) [abstract no. 14]. Eur J Cancer 1999 Apr; 35 Suppl. 2: S52
68.
Salminen E, Bergman M, Huhtala S, et al. Docetaxel: standard recommended dose of 100 mg/m2 is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy — a phase II single-center study. J Clin Oncol 1999 Apr; 17(4): 1127–31PubMed
69.
Löffler TM, Dröge C, Hausamen TU. Update on dose-dense weekly Taxotere (R) in metastatic breast cancer [abstract no. O15]. Ninth International Congress on Anti-Cancer Treatment; 1999 Feb 2–5; Paris, France,133
70.
Scholz U, Lück H-J, Rittershaus A, et al. Weekly docetaxel treatment in metastatic breast cancer: a phase I/II study [abstract no. 228]. Breast Cancer Res Treat 1998; 50(3): 262
71.
Burstein HJ, Younger J, Bunnell CA, et al. Weekly docetaxel (Taxotere) for metastatic breast cancer: a phase II trial [abstract no. 484]. Proc Am Soc Clin Oncol 1999; 18: 127a
72.
Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981 Jan; 47: 207–14PubMedCrossRef
73.
Adachi I, Watanabe T, Takashima S, et al. A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer. Br J Cancer 1996 Jan; 73: 210–6PubMedCrossRef
74.
Bonneterre J, Spielman M, Guastalla J-P, et al. Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience. Eur J Cancer 1999; 35(10): 1431–9PubMedCrossRef
75.
Alexopoulos CG, Rigatos G, Efremidou A, et al. Phase II study of taxotere monotherapy in previously treated patients (pts) with advanced breast cancer (ABC) [abstract no. 680]. Eur J Cancer A 1997 Sep; 33 Suppl. 8: S153CrossRef
76.
Bonneterre J, Guastalla JP, Fumoleau P, et al. A phase II trial of docetaxel in patients (pts) with anthracycline resistant (AR) metastatic breast cancer (MBC) [abstract no. 305]. Breast Cancer Res Treat 1996; 37 Suppl.: 89CrossRef
77.
Coleman RE, Howell A, Eggleton SPH, et al. An open phase II study of taxotere in 42 patients with liver metastases from breast cancer [abstract no. 69P]. Ann Oncol 1998; 9 Suppl. 4: 15
78.
Constenla M, Carrete N, Lorenzo I, et al. Phase II trial of docetaxel and lenograstim in anthracycline-resistant metastatic breast cancer [abstract no. O20]. Ninth International Congress on Anti-Cancer Treatment; 1999 Feb 2–5; Paris, France, 134
79.
Cufer T, Lazarev A, El GK, et al. Preliminary data of a phase II trial of taxotere (TXT) 100 or 75 mg/m2 as 2nd line chemotherapy (CT) in patients (pts) with metastatic breast cancer (MBC) with stratification according to prognosis factors [abstract no. 78P]. Ann Oncol 1998; 9 Suppl. 4: 17
80.
Ferraresi V, Vaccaro A, Milella M, et al. Docetaxel (DT) in anthracycline-pretreated advanced breast cancer (ABC): toxicity and activity [abstract no. 88P]. Ann Oncol 1998; 9 Suppl. 4: 19
81.
Gorbounova V, Borisova T, Orel N. The increasing of effect after discontinuation of the treatment with Taxotere in patients with breast cancer [abstract no. 84]. Eur J Cancer A 1998 Sep; 34 Suppl. 5: S21CrossRef
82.
Kusenda Z, Geurs F, Kerger J, et al. Docetaxel (D) activity in a compassionate-use program for “poor-risk” metastatic breast cancer (MBC): a single center experience [abstract no. 102P]. Ann Oncol 1996; 7 Suppl. 5: 24
83.
Litvachky A, Pescia A, Gramuglia V, et al. Phase IV, non-randomized, open trial of Taxotere (TXT) — single agent in anthracycline (A) relapsed metastatic breast cancer (MBC) [abstract no. P39]. Ninth International Congress on Anti-Cancer Treatment; 1999 Feb 2–5; Paris, France, 193
84.
O’Brien MER, Leonard RC, Barrett-Lee PJ, et al. Docetaxel in the community setting: an analysis of 377 breast cancer patients treated with docetaxel (Taxotere) in the UK. Ann Oncol 1999 Feb; 10: 205–10PubMedCrossRef
85.
Ravdin PM, Burris III HA, Cook G, et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 1995 Dec; 13: 2879–85PubMed
86.
Taguchi T, Mori S, Abe R, et al. Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent breast cancer [in Japanese]. Gan to Kagaku Ryoho 1994 Nov; 21: 2625–32PubMed
87.
Taguchi T, Hirata K, Kunii Y, et al. An early phase II clinical study of RP56976 (docetaxel) in patients with breast cancer [in Japanese]. Gan to Kagaku Ryoho 1994 Oct; 21: 2453–60PubMed
88.
Valero V, Jones SE, Von Hoff DD, et al. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol 1998 Oct; 16(10): 3362–8PubMed
89.
Van Vaerenbergh W, Paridaens R, Thomas J, et al. Docetaxel is a potent cytotoxic drug in the treatment of advanced breast cancer. Acta Clin Belg 1998 Aug; 53(4): 264–9PubMed
90.
Vorobiof DA, Chasen MR, Moeken R. Phase II trial of single agent docetaxel in previously treated patients (pts) with advanced breast cancer (ABC) [abstract no. 138]. Ann Oncol 1996; 7 Suppl. 5: 31
91.
Wilke H, Joosens E, Hess D, et al. Extensive clinical experience with Taxotere (T) is 1st and 2nd line treatment (tt) at 100 mg/m2 in locally advanced (LA) or metastatic breast cancer (MBC) [abstract no. 1283]. Eur J Cancer 1999; 35 Suppl. 4: S320CrossRef
92.
Nabholtz J-M, Senn HJ, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol 1999 May; 17: 1413–24PubMed
93.
Chan S, Friedrichs K, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999; 17: 2341–23540PubMed
94.
Bonneterre J, Roche H, Monnier A, et al. Docetaxel (D) versus 5 fluorouracil-vinorelbine (FUN) in patients (pts) with metastatic breast cancer (MBC) as second line chemotherapy: a phase III study [abstract no. 223]. Breast Cancer Res Treat 1998; 50(3): 261
95.
Sjöström J, Blomqvist C, Mouridsen H, et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 1999; 35: 1194–201PubMedCrossRef
96.
Löffler TM. Is there a place for “dose-dense” weekly schedules of the taxoids? Semin Oncol 1998 Oct; 25 Suppl. 12: 32–4PubMed
97.
Fumoleau P, Chevallier B, Kerbrat P, et al. A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC. Ann Oncol 1996 Feb; 7: 165–71PubMedCrossRef
98.
Trudeau ME, Eisenhauer EA, Higgins BP, et al. Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 1996 Feb; 14: 422–8PubMed
99.
Borisova TA, Orel NF, Pirogova NA, et al. Phase II study of Taxotere in advanced or/and metastatic breast cancer as a first or second line of treatment [abstract no. 132]. Ann Oncol 1998; 9 Suppl. 4: 28
100.
Hudis CA, Seidman AD, Crown JP, et al. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1996 Jan; 14: 58–65PubMed
101.
Chevallier B, Fumoleau P, Kerbrat P, et al. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 1995 Feb; 13: 314–22PubMed
102.
Dieras V, Chevallier B, Kerbrat P, et al. A multicentre phase II study of docetaxel 75 mg m−2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. Br J Cancer 1996 Aug; 74: 650–6PubMedCrossRef
103.
Salimi M, Mir MR. Dose-dense weekly docetaxel and CBDCA in adriamycin-resistant metastatic breast cancer (MBC) [abstract no. 178]. Eur J Cancer A 1998 Sep; 34 Suppl. 5: S44CrossRef
104.
Bernard A, Antoine E-C, Gozy M, et al. Docetaxel (D) and cisplatin (P) combination in anthracycline-pretreated advanced breast cancer (ABC): preliminary results of a phase II study [abstract no. 229]. Breast Cancer Res Treat 1997 Oct; 46: 58
105.
Llombart-Cussac A, Spielmann M, Dohollou N, et al. Cis-platinum-Taxotere phase I/II trial in patients with anthracyclin-resistant advanced breast cancer (ABC) [abstract no. 629]. 33rd Proc Am Soc Clin Oncol 1997 May 17; 16: 180a
106.
Martin M, Antón A, Esteban C, et al. FLEXI-TAC chemotherapy for locally advanced breast cancer [abstract no. O19]. Ninth International Congress on Anti-Cancer Treatment; 1999 Feb 2–5; Paris, France, 134
107.
Polyzos A, Tsavaris N, Goga E, et al. A phase II study of docetaxel and epirubicin in patients with advanced breastcancer [abstract no. 122]. Anticancer Res 1998 Sep–Oct; 18: 3872
108.
Dent J, Dodwell D, Bradley C, et al. Phase I/II study of taxotere (T) in combination with epirubicin (E) and protracted venous infusion (PVI) 5-fluorouracil (F) in patients with recurrent or metastatic breast cancer (BC). A Yorkshire Collaborative Breast Cancer Study [abstract no. P291]. Br J Cancer 1999; 80 Suppl. 2: 101
109.
Ando M, Watanabe T, Sasaki Y, et al. Aphase I trial of docetaxel and 5-day continuous infusion of 5-fluorouracil in patients with advanced or recurrent breast cancer. Br J Cancer 1998 Jun; 77: 1937–43PubMedCrossRef
110.
Cottu PH, Cojean-Zelek I, Lerebours F, et al. Docetaxel associated with 5-fluorouracil for patients with breast cancer: a phase I–II pilot study [abstract no. 42P]. Ann Oncol 1998; 9 Suppl. 4: 9
111.
Lortholary A, Maillart P, Delva R, et al. Docetaxel (D) in combination with continuous infusion 5fluorouracil (CI 5FU) in metastatic breast cancer (MBC) patients (pts) after anthracycline (ANT) failure: phase I dose-escalation [abstract no. 413]. Breast Cancer Res Treat 1997 Oct; 46: 96
112.
Michelotti A, Tibaldi C, Repetto L, et al. Taxotere in metastatic breast cancer patients pretreated with anthracycline and taxol [abstract no. 239]. Breast Cancer Res Treat 1998; 50(3): 265
113.
Fountzilas G, Bafaloukos D, Nikolaides C, et al. Docetaxel (D) and gemcitabine (G) in anthracycline-resistant advanced breast cancer (AR-ABC) [abstract no. 121]. Ann Oncol 1998; 9 Suppl. 4: 26
114.
Mavroudis D, Malamos N, Alexopoulos A, et al. Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Ann Oncol 1999 Feb; 10: 211–5PubMedCrossRef
115.
von Minckwitz G, Costa S-D, Blohmer J, et al. Preoperative chemotherapy of breast carcinoma [in German]. Zentralbl Chir 1998; 123 Suppl. 5: 138–41
116.
Bueso P, Mayordomo JI, Cajal R, et al. Final report of a phase II trial with docetaxel + vinorelbine for anthracyclin-refractory metastasic breast cancer [abstract no. 24]. Eur J Cancer 1999 Apr; 35 Suppl. 2: S53
117.
Galvez C. Doxetaxel (D) in combination with vinorelbine (VNB) with GM-CSF in Taxol refractory metastatic breast cancer (MBC). Preliminary results of phase II [abstract no. P119]. Eighth International Congress on Anti-Cancer Treatment; 1998 Feb 3–6; Paris, France, 165
118.
Oncopaz Cooperative Group Study. Docetaxel-vinorelbine in anthracycline resistant disseminated breast carcinoma. An Oncopaz Cooperative Group Study [abstract no. 10]. Eur J Cancer 1999 Apr; 35 Suppl. 2: S52
119.
Baltali E, Özisik Y, Firat D, et al. Combination of docetaxel (T) and doxorubicin (D) as first-line chemotherapy in metastatic breast cancer (MBC) [abstract no. P42]. Ninth International Congress on Anti-Cancer Treatment; 1999 Feb 2–5; Paris, France, 194
120.
Nabholtz JM, Falkson G, Campos D, et al. A phase III trial comparing doxorubicin (A) and docetaxel (T) (AT) to doxorubicin and cyclophosphamide (AC) as first line chemotherapy for MBC [abstract no. 485]. Proc Am Soc Clin Oncol 1999; 18: 127a
121.
Misset JL, Dieras V, Gruia G, et al. Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer. Ann Oncol 1999; 10: 553–60PubMedCrossRef
122.
Nabholtz J-M, Mackey J, Smylie M, et al. Taxane-based three-drug combination in metastatic and adjuvant treatment of breast cancer. Semin Oncol 1998 Oct; 25(5) Suppl. 12: 27–31PubMed
123.
Palmeri S, Leonardi V, Ferraù F, et al. Doxorubicin (DXR) + docetaxel (DOC) as first line therapy of advanced breast cancer (ABC) patients: preliminary results of a multicentric phase II study [abstract no. 204]. Tumori 1998 Sep–Oct; 84 Suppl. 1: 84
124.
Sparano JA, Hu P, Schaefer PL, et al. Phase II trial of doxorubicin and docetaxel (Taxotere) plus granulocyte-colony stimulating factor (G-CSF) in metastatic breast cancer (MBC): an Eastern Cooperative Oncology Group Study (E1196) [abstract no. 27]. Breast Cancer Res Treat 1998; 50(3): 233
125.
Vallejos C, Nunez P, Orlandi L, et al. Taxotere (T) and doxorubicin (D) combination: a phase II South American study in first line treatment (tt) of metastatic breast cancer (MBC) [abstract no. 1324]. Eur J Cancer 1999; 35 Suppl. 4: S329CrossRef
126.
Shogan J, Troetschel M, Ellis P, et al. Phase II trial evaluating Adriamycin and Taxotere (AT) with GM-CSF support as first-line therapy for women with metastatic breast cancer [abstract no. 439]. Proc Am Soc Clin Oncol 1999; 18: 116
127.
Crown J, Fumoleau P, Kerbrat P, et al. Phase I trial of docetaxel (D) with cisplatin (P) as first-line chemotherapy of metastatic breast cancer (MBC) [abstract no. 821]. 33rd Proc Am Soc Clin Oncol 1997 May 17; 16: 233a
128.
Twelves C, Roche H, Vasey PA, et al. A phase I–II study of docetaxel (D) plus cyclophosphamide (C) as first line chemotherapy (CT) in metastatic breast cancer (MBC) [abstract no. 239]. Breast Cancer Res Treat 1997 Oct; 46(1): 60
129.
Valero V. Combination docetaxel/cyclophosphamide in patients with advanced solid tumors. Oncology Huntingt 1997 Aug; 11(8) Suppl. 8: 34–6PubMed
130.
Fabi A, Venturini M, Michelotti A, et al. Combination of epirubicin (EPI) and Taxotere (TXT) with and without G-CSF in locally advanced (LABC) and metastatic breast cancer (MBC): a phase I–II study [abstract no. P72]. Ninth International Congress on Anti-Cancer Treatment; 1999 Feb 2–5; Paris, France, 201
131.
Kouroussis C, Xydakis E, Potamianou A, et al. Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: a multicenter dose-escalation study. Ann Oncol 1999; 10: 547–52PubMedCrossRef
132.
Pagani O, Sessa C, Martinelli G, et al. Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer. Ann Oncol 1999; 10: 539–45PubMedCrossRef
133.
Kerbrat P, Viens P, Roché H, et al. Docetaxel (D) in combination with epirubicin (E) as 1 st line chemotherapy (CT) of metastatic breast cancer (MBC): Final results [abstract no. 579]. Proc Am Soc Clin Oncol 1998; 17: 151a
134.
Kouroussis C, Androulakis N, Kakolyris S, et al. Dose-escalation study of docetaxel in combination with mitoxantrone as first-line treatment in patients with metastatic breast cancer. J Clin Oncol 1999 Mar; 17: 862–9PubMed
135.
Fumoleau P, Delecroix V, Perrocheau G, et al. Docetaxel (D) in combination with vinorelbine (V) as 1st line CT in pts with metastatic breast cancer (MBC): final results [abstract no. 232]. Proc Am Soc Clin Oncol 1996 Mar; 15: 142
136.
Sparano JA, Malik UR, Einzig A, et al. Phase I trial of liposomal doxorubicin (Doxil) and docetaxel (Taxotere) in patients (pts) with advanced breast cancer (ABC) [abstract no. 235]. Breast Cancer Res Treat 1998; 50(3): 264
137.
Ravdin PM. Emerging role of docetaxel (Taxotere) in the adjuvant therapy of breast cancer. Semin Oncol 1999; 26 Suppl. 9: 20–3PubMed
138.
Costa SD, von Minckwitz G, Raab G, et al. The role of docetaxel (Taxotere) in neoadjuvant chemotherapy of breast cancer. Semin Oncol 1999; 26 Suppl. 9: 24–31PubMed
139.
Gademann G, von Minckwitz G, Costa S, et al. GEPARDO — a German trial of preop. chemotherapy with ADoc in breast cancer: first promising results [abstract no. 798]. Eur J Cancer 1999; 35 Suppl. 4: S205CrossRef
140.
Gradishar WJ, Loh K, Erban J, et al. Preliminary results from a phase II study of (Taxotere) docetaxel as primary chemotherapy followed by doxorubicin and cyclophosphamide in stage III breast cancer [abstract]. Proc Am Soc Clin Oncol 1997 May 17; 16: 171
141.
Laurence V, Girre V, Extra JM, et al. Phase II study of sequential docetaxel (Taxotere, TXT) and doxorubicin (DOX) as primary chemotherapy (CT) for large operable breast cancer (BC) [abstract no. 791]. Eur J Cancer 1999; 35 Suppl. 4: S203CrossRef
142.
Miller KD, McCaskill-Stevens W, Sisk J, et al. Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: a randomized pilot trial of the Hoosier Oncology Group. J Clin Oncol 1999; 17: 3033–7PubMed
143.
Salimi M, Davaee M. Docetaxel and doxorubicin as neoadjuvant chemotherapy in locally — advanced breast cancer [abstract no. P10]. Ninth International Congress on Anti-Cancer Treatment; 1999 Feb 2–5; Paris, France, 186
144.
Smith IC, Hutcheon AW, Walker LG, et al. Primary chemotherapy in breast cancer: significantly enhanced clinical and pathological response with docetaxel [abstract no. 901]. Eur J Cancer 1999; 35 Suppl. 4: S230CrossRef
145.
von Minckwitz G, Dan Costa S, Eiermann W, et al. Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel. J Clin Oncol 1999; 17: 1999–2005
146.
Wynendaele W, Paridaens R, Wildiers J, et al. Locally advanced breast cancer (LABC): neoadjuvant chemotherapy with sequential doxorubicin (DOX) and docetaxel (DOC) [abstract no. 813]. Eur J Cancer 1999; 35 Suppl. 4: S208CrossRef
147.
Antoine EC, Chollet P, Monfardini S, et al. Sequential administration of docetaxel (D) (Taxotere) followed by AC in first line metastatic breast cancer (MBC) patients (pts): final results [abstract no. 91P]. Ann Oncol 1998; 9 Suppl. 4: 19–20
148.
Tubiana-Hulin M, Namer M, Tubiana-Mathieu N, et al. Alternating and sequential schedules of Taxotere/FEC 75 in the first line treatment of metastatic breast cancer [abstract no. 57O]. Ann Oncol 1998; 9 Suppl. 4: 12
149.
Valencak J, Kornek GV, Haider K, et al. Treatment of advanced refractory breast cancer with docetaxel alternating with epirubicin and cyclophosphamide (EC) + G-CSF [abstract no. 689]. Ann Oncol 1998; 9 Suppl. 2: 180
150.
Mendez M, Quiben R, Lopez P. Sequential therapy of taxol followed by vinorelbine and cisplatin as second line in advanced breast cancer [abstract no. 1309]. Eur J Cancer 1999; 35 Suppl. 4: S326CrossRef
151.
Paridaens R, Van Aelst F, Georgoulias G, et al. A phase II randomized study of doxorubicin (A) alternated to docetaxel (T) (ALT) vs sequential administration of 4 cy of t followed by 4 cy of a (seq) as 1 st line ct in mbc pts [abstract no. 1259]. Eur J Cancer 1999; 35 Suppl. 4: S314CrossRef
152.
Koroleva I, Wojtukiewicz M, Zaluski J, et al. Preliminary data of a phase II randomized trial of taxotere (TXT) and doxorubicin (DOX) given simultaneously or sequentially as 1st line chemotherapy (CT) for metastatic breast cancer (MBC) [abstract no. 1272]. Eur J Cancer 1999; 35 Suppl. 4: S317CrossRef
153.
Lamb HM, Wiseman LR. Docetaxel: a pharmacoeconomic review of its use in the treatment of metastatic breast cancer. Pharmacoeconomics 1998 Oct; 14: 447–59PubMedCrossRef
154.
Peters BG, Dunphy IF, Hill JJ. Docetaxel and paclitaxel for the treatment of anthracycline-resistant metastatic breast cancer: a pharmacoeconomic model. PsT 1997 Nov; 22: 543–52
155.
Launois R, Reboul-Marty J, Henry B, et al. A cost-utility analysis of second-line chemotherapy in metastatic breast cancer: docetaxel versus paclitaxel versus vinorelbine. Pharmacoeconomics 1996 Nov; 10: 504–21PubMedCrossRef
156.
Brown RE, Hutton J. Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients. Anticancer Drugs 1998 Nov; 9: 899–907PubMedCrossRef
157.
Hutton J, Brown R, Borowitz M, et al. A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer. Pharmacoeconomics 1996; 9 Suppl. 2: 8–22PubMedCrossRef
158.
Leung PP, Tannock IF, Oza AM, et al. Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer. J Clin Oncol 1999; 17(10): 3082–90PubMed
159.
Ajani JA, Welch SR, Raber MN, et al. Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 1990; 8: 147–59PubMedCrossRef
160.
World Health Organization. Handbook for reporting results of cancer treatment. WHO publication no. 48 ed. Geneva, Switzerland: World Health Organization, 1979
161.
Furue H, Hara Y, Imai Y, et al. Criteria for the evaluation of effect reinforcement of solid cancer chemotherapy [in Japanese]. Nippon Gan Chiryo Gakkai Shi 1986; 21: 943–53
162.
Cortes JE, Pazdur R. Docetaxel. J Clin Oncol 1995 Oct; 13: 2643–55PubMed
163.
Balmaceda C, Forsyth P, Seidman AD, et al. Peripheral neuropathy in patients receiving taxotere chemotherapy [abstract]. Ann Neurol 1993 Aug; 34: 313
164.
van den Bent MJ, Hilkens PHE, Verwey J, et al. Docetaxel induces a mild dose-dependent sensory neuropathy [abstract no. 574P]. Neurology 1995 Apr; 45 Suppl. 4: A322
165.
Pronk LC, Hilkens PHE, van den Bent MJ, et al. Corticosteroid co-medication does not reduce the incidence and severity of neurotoxicity induced by docetaxel. Anticancer Drugs 1998 Oct; 9: 759–64PubMedCrossRef
166.
Pronk LC, van Putten WLJ, van Beurden V, et al. The venotonic drug hydroxyethylrutosiden does not prevent or reduce docetaxel-induced fluid retention: results of a comparative study. Cancer Chemother Pharmacol 1999; 43: 173–7PubMedCrossRef
167.
Behar A, Pujade-Lauraine E, Maurel A, et al. The pathophysiological mechanism of fluid retention in advanced cancer patients treated with docetaxel, but not receiving corticosteroid comedication. Br J Clin Pharmacol 1997 Jun; 43: 653–8PubMedCrossRef
168.
Oulid-Aïssa D, Béhar A, Spielmann M, et al. Management of fluid retention syndrome in patients treated with Taxotere (docetaxel): effect of premedication [abstract no. 1614]. Proc Am Soc Clin Oncol 1994 Mar; 13: 465
169.
Semb KA, Aamdal S, Øian P. Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J Clin Oncol 1998 Oct; 16: 3426–32PubMed
170.
Webster LK, Linsenmeyer ME, Rischin D, et al. Plasma concentrations of polysorbate 80 measured in patients following administration of docetaxel or etoposide. Cancer Chemother Pharmacol 1997 Apr; 39: 557–60PubMedCrossRef
171.
Chan S, Winterbottom L, Gardner S. Response to dexamethasone in patients with fluid retention after docetaxel [letter]. Lancet 1996 May 25; 347: 1486–7PubMedCrossRef
172.
Riva A, Fumoleau P, Roché H, et al. Efficacy and safety of different corticosteroid (C) premedications (P) in breast cancer (BC) patients (pts) treated with Taxotere (T) [abstract no. 660]. 33rd Proc Am Soc Clin Oncol 1997 May 17; 16: 188a
173.
Piccart MJ, Klijn J, Paridaens R, et al. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol 1997 Sep; 15: 3149–55PubMed
174.
Aventis Pharma. Taxotere (docetaxel) US prescribing information. Collegeville, PA., USA, 1999
175.
Aventis. Taxotere (docetaxel) European summary of product characteristics. Antony Cedex, France, Jan 2000
176.
Wanders J, Schrijvers D, Bruntsch U, et al. The EORTC-ECTG experience with acute hypersensitivity reactions (HSR) in Taxotere studies [abstract no. 94]. Proc Am Soc Clin Oncol 1993 Mar; 12: 73
177.
Nabholtz J-M, Mackey JR, Smylie M, et al. Final results of a phase II study of taxotere (docetaxel, D), doxorubicin and cyclophosphamide in the treatment of metastatic breast cancer [abstract]. Eur J Cancer A 1998 Sep; 34 Suppl. 5: 43CrossRef
178.
Llombart-Cussac A, Pivot X, Spielmann M. Docetaxel chemotherapy induces transverse superficial loss of the nail plate [letter]. Arch Dermatol 1997 Nov; 133: 1466–7PubMedCrossRef
179.
Auvinet M, Dahan S, Dingremont C, et al. Yellow nails [in French]. Rev Med Interne 1998 May; 19: 353–4PubMedCrossRef
180.
Vanhooteghem O, André J, Vindevoghel A, et al. Docetaxel-induced subungual hemorrhage. Dermatology 1997; 194: 419–20PubMedCrossRef
181.
Nabholtz J-M. Docetaxel (Taxotere) plus doxorubicin-based combinations: the evidence of activity in breast cancer. Semin Oncol 1999 June; 26(3) Suppl. 9: 7–13PubMed
182.
Di Leo A, Crown J, Nogaret LM, et al. Doxorubicin (A) followed by docetaxel (T) versus doxorubicin + docetaxel in the adjuvant treatment of breast cancer (BC) [abstract no. 166]. Eur J Cancer 1998; 34 Suppl. 5: S41
183.
Sparano JA. Doxorubicin/taxane combinations: cardiac toxicity and pharmacokinetics. Semin Oncol 1999; 26 Suppl. 9: 14–9PubMed
184.
Consensus summary on breast cancer. Semin Oncol 1999 Feb; 26 Suppl. 2: 27
185.
Luoma L, Hakamies-Blomqvist M-L, Sjöström J, et al. Preliminary results from quality of life (QOL) study in metastatic breast cancer: a randomised study comparing Taxotere (T) to sequential methotrexate-fluorouracil (MF) in advanced anthracycline resistant breast cancer, a phase III study [abstract no. 245]. 34th Proc Am Soc Clin Oncol 1998 May 16–19; 17: 63
186.
187.
Rubens RD. Key issues in the treatment of advanced breast cancer: expectations and outcomes. Pharmacoeconomics 1996; 9 Suppl. 2: 1–7PubMedCrossRef
188.
de Valeriola D, Awada A, Roy J-A, et al. Breast cancer therapies in development. A review of their pharmacology and clinical potential. Drugs 1997 Sep; 54(3): 385–413
189.
Brown RE, Burrell A. The economic advantages of response in the treatment of advanced breast cancer. J Drug Assess 1999; 2(2): 181–7
190.
191.
Burris HA, Raefsky E, Albain K, et al. Docetaxel and Herceptin as first- or second-line therapy for women with HER-2 overexpressing metastatic breast cancer [abstract no. 518]. Breast Cancer Res Treat 1999; 57(1): 123
Metadata
Title
Docetaxel
An Update of its Use in Advanced Breast Cancer
Authors
David P. Figgitt
Lynda R. Wiseman
Publication date
01-03-2000
Publisher
Springer International Publishing
Published in
Drugs / Issue 3/2000
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200059030-00015

Other articles of this Issue 3/2000

Drugs 3/2000 Go to the issue

Disease Management

Drugs Used to Treat Spasticity

Adis Drug Evaluation

Miglitol

Adis New Drug Profile

Alosetron

Adis New Drug Profile

Alosetron

Adis New Drug Profile

Alosetron

Review Article

Kinase Inhibitors in Cancer Therapy